Individualizing MS Treatment: Practical Applications

Volume 2, Issue 6

Individualizing MS Treatment: Practical Applications

In this issue:

In this podcast, Drs. Daniel Ontaneda, Jenny Feng and Gabrielle Macaron from the Cleveland Clinic follow up on their recent eMS Newsletter Issue (V2; No.5) to discuss some of the practical applications of individualizing MS therapy.

Learning objectives:

Explain stratifying patients based on positive and negative predictors as a key part of individualizing therapy
Describe challenges in developing new MS therapies, particularly for progressive MS.

Authors:

Jenny Feng, MD

Neuroimmunology Fellow
Cleveland Clinic Neurological Institute
Cleveland, OH

Daniel Ontaneda, MD

Staff Neurologist
Cleveland Clinic Neurological Institute
Cleveland, OH

Gabrielle Macaron, MD

Neuroimmunology Fellow
Cleveland Clinic Neurological Institute
Cleveland, OH

Guest Faculty Disclosures

Dr. Feng has disclosed that she has served on an advisory board for Sanofi-Aventis. She also receives Sylvia Lawry fellowship funding from the National MS Society.

Dr. Ontaneda has disclosed that he has acted as a consultant for Novartis AG, Biogen Inc., and Genentech, Inc. and has performed contracted research and received research funds from Genentech, Inc., Genzyme Corporation, and Novartis AG.

Dr. Macaron has disclosed that she has served on a scientific advisory board for Genentech. She previously received fellowship funding from Biogen Inc and currently receives fellowship funding through the National MS Society.

Unlabeled/Unapproved Uses

The authors have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Program Director:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Dr. Feng has disclosed that she has served on an advisory board for Sanofi-Aventis. She also receives Sylvia Lawry fellowship funding from the National MS Society.

Unlabeled/Unapproved Uses:

The authors have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Length of activity:

0.5 hour Physicians

Launch date: June 29, 2019
Expiration date: June 28, 2021

Start Issue